For patients with chronic hepatitis B virus (HBV) infection with virologic suppression with nucleoside or nucleotide analog ...

When interferon treatment was being developed in the Soviet Union, this was effectively overlooked in the West during the cold-war era due to its concentration on the development of vaccines.

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, with a survival rate of just 11%. A primary culprit ...

Present interferon-based therapy for chronic hepatitis C is limited by both efficacy and tolerability. Telaprevir and boceprevir are the first two direct-acting antiviral drugs (DAAs) that inhibit ...

The regulator HIF1α functions in a cancer-microenvironment that lacks oxygen, and it may be involved in resistance to immune ...

“While 48 weeks of interferon can be used as a standard of care treatment for HBV patients, historically less than 10% of patients experience a functional cure. Here, with the combination of ...

Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-α as first-line treatment for patients with metastatic renal-cell carcinoma.

Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, carrying a greater risk of developing cirrhosis and its ...

ruzotolimod or pegylated interferon (peginterferon) alfa-2a, in persons who had virologic suppression with NA therapy. We conducted this trial according to the Good Clinical Practice guidelines of ...

treatment-experienced (17) Arm 1: ABT-450/r (250/100 mg) + ABT-333 + RBV × 12 weeks Arm 2: ABT-450/r(150/100 mg) + ABT-333 + RBV × 12 weeks Arm 3: ABT-450/r(150/100 mg) + ABT-333 + RBV × 12 ...

"While 48 weeks of interferon can be used as a standard of care treatment for HBV patients, historically less than 10% of patients experience a functional cure. Here, with the combination of imdusiran ...